The variances of hematology of gurami (Osphronemus gouramy) which is vaccinated and challenged by Aeromonas hydrophila

Freshwater fish that became the leading commodity of gourami. Fish cultivation is often experienced constraints of infection from motile aeromonas septicaemia (MAS), also known as red spotting disease caused by bacteria Aeromonas hydrophila. A vaccine is an effective preventive measure because in th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:IOP conference series. Earth and environmental science 2020-02, Vol.441 (1), p.12042
Hauptverfasser: Alfaniah, D, Kusdarwati, R, Rozi, Handijatno, D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Freshwater fish that became the leading commodity of gourami. Fish cultivation is often experienced constraints of infection from motile aeromonas septicaemia (MAS), also known as red spotting disease caused by bacteria Aeromonas hydrophila. A vaccine is an effective preventive measure because in this way immune can be obtained only once or twice vaccine administration until the fish is harvested. This study aims to determine the haematological picture of gourame (Osphronemus gouramy) that vaccinated and challenged bacteria Aeromonas hydrophila. This research is an experimental research using completely randomized design which consists of 5 treatments and 4 replications. The treatment of this study was the difference of vaccine dose ie A (control +) fish injected vaccine without any challenge test, B (control -) fish injected NaCl Physiological and tested challenge, C vaccine dose 104 CFU/mL, D vaccine dose 105 CFU/mL, and E vaccine dose of 106 CFU/mL. The results of this study showed vaccinations and tests of bacteria Aeromonas hydrophila in gouramy can give effect to total erythrocytes, hemoglobin, leukocyte total, and leukocyte differential. The 106 cell/mm3 (E) vaccine dose provides the best (responsive immune response) effectiveness compared to the other two doses.
ISSN:1755-1307
1755-1315
DOI:10.1088/1755-1315/441/1/012042